Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGMT

Sagimet Biosciences Inc

Dec 01 • 04:00PM ET

3.79

Dollar change -0.03
Percentage change -0.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	47.84%	Shs Outstand	21.38M	Perf Week	-7.56%
Market Cap	81.03M	Forward P/E	-	EPS next Y	-	Insider Trans	0.76%	Shs Float	11.15M	Perf Month	6.76%
Income	-	PEG	-	EPS next Q	-0.58	Inst Own	52.16%	Short Float / Ratio	5.14% / 4.22	Perf Quarter	-68.42%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.57M	Perf Half Y	-
Book/sh	4.58	P/B	0.83	EPS next Y	-	ROA	-	Target Price	42.67	Perf Year	-
Cash/sh	4.76	P/C	0.80	EPS next 5Y	-	ROE	-	52W Range	2.13 - 18.33	Perf YTD	-76.24%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-79.32%	Beta	-
Dividend %	-	Quick Ratio	20.36	Sales past 5Y	0.00%	Gross Margin	-	52W Low	77.93%	ATR	0.64
Employees	10	Current Ratio	20.36	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.62	Volatility	18.92% 19.30%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-14.48%	Profit Margin	-	Rel Volume	1.07	Prev Close	3.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 13 BMO	Payout	-	Avg Volume	135.77K	Price	3.79
Recom	1.00	SMA20	13.99%	SMA50	-27.73%	SMA200	-60.00%	Volume	144,989	Change	-0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight	$67
Aug-08-23	Initiated	JMP Securities	Mkt Outperform	$30
Aug-08-23	Initiated	Goldman	Buy	$33

Nov-28-23 08:00AM	Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit (GlobeNewswire)
Nov-22-23 08:00AM	Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +13.58%
Nov-13-23 08:00AM	Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.73%
Nov-10-23 08:30AM	Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023 (GlobeNewswire) -7.68%
Oct-24-23 11:00AM	Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023 (GlobeNewswire)
04:05PM	Loading…
Oct-18-23 04:05PM	Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference (GlobeNewswire)
Sep-27-23 04:05PM	Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Aug-29-23 10:21AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
Aug-21-23 04:02PM	Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-15-23 04:04PM	Sagimet Biosciences Announces Closing of Underwriters Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering (GlobeNewswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Jul-20-23 04:05PM	Sagimet Biosciences Announces Leadership Changes (GlobeNewswire)
Jul-13-23 09:10PM	Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Happel David	President & CEO	Nov 16	Buy	2.35	590	1,386	590	Nov 20 09:59 PM
Kemble George	Executive Chairman	Sep 07	Option Exercise	0.79	5,630	4,448	5,630	Sep 08 04:15 PM
SEIDENBERG BETH C	Director	Jul 18	Buy	16.00	46,875	750,000	46,875	Jul 20 04:20 PM
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18	Buy	16.00	30,000	480,000	3,850,275	Jul 20 06:56 PM
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18	Sale	16.00	662	10,592	3,820,275	Jul 20 06:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGMT

Sagimet Biosciences Inc

Upgrade your FINVIZ experience